JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUMAComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosDepartamentos/InstitutosEditoresEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosDepartamentos/InstitutosEditores

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    DE INTERÉS

    Datos de investigaciónReglamento de ciencia abierta de la UMAPolítica de RIUMAPolitica de datos de investigación en RIUMAOpen Policy Finder (antes Sherpa-Romeo)Dulcinea
    Preguntas frecuentesManual de usoContacto/Sugerencias
    Ver ítem 
    •   RIUMA Principal
    • Investigación
    • Artículos
    • Ver ítem
    •   RIUMA Principal
    • Investigación
    • Artículos
    • Ver ítem

    Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease.

    • Autor
      Ramos, Blanca; Baglietto-Vargas, David; del Rio, Juan Carlos; Moreno-González, Inés; Santa-Maria, Consuelo; Jiménez, Sebastián; Caballero, Cristina; López-Téllez, Juan Félix; Khan, Zafar U.; Ruano, Diego; Gutiérrez-Pérez, AntoniaAutoridad Universidad de Málaga; Vitorica Ferrández, Javier
    • Fecha
      2006-11
    • Editorial/Editor
      Elsevier
    • Palabras clave
      Alzheimer, Enfermedad de
    • Resumen
      At advanced stages, Alzheimer's disease (AD) is characterized by an extensive neuronal loss. However, the early neurodegenerative deficiencies have not been yet identified. Here we report an extensive, selective and early neurodegeneration of the dendritic inhibitory interneurons (oriens-lacunosum moleculare, O-LM, and hilar perforant path-associated, HIPP, cells) in the hippocampus of a transgenic PS1 × APP AD model. At 6 months of age, from 22 different pre- and postsynaptic mRNA markers tested (including GABAergic, glutamatergic and cholinergic markers), only the expression of somatostatin (SOM) and NPY neuropeptides (O-LM and HIPP markers) displayed a significant decrease. Stereological cell counting demonstrated a profound diminution (50–60%) of SOM-immunopositive neurons, preceding the pyramidal cell loss in this AD model. SOM population co-expressing NPY was the most damaged cell subset. Furthermore, a linear correlation between SOM and/or NPY deficiency and Abeta content was also observed. Though the molecular mechanism of SOM neuronal loss remains to be determined, these findings might represent an early hippocampal neuropathology. Therefore, SOM and NPY neuropeptides could constitute important biomarkers to assess the efficacy of potential early AD treatments.
    • URI
      https://hdl.handle.net/10630/36524
    • DOI
      https://dx.doi.org/10.1016/j.neurobiolaging.2005.09.022
    • Compartir
      RefworksMendeley
    Mostrar el registro completo del ítem
    Ficheros
    Early neuropathology of somatostatin.pdf (1.303Mb)
    Colecciones
    • Artículos

    Estadísticas

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
     

     

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA